Epsilon M&A Deal Report - SELAS Bio-Clinic
Transaction Multiples for the Valuation of Private Companies
Fund raising led by Azulis Capital and Galia Gestion / SELAS Bio-Clinic
No EMAT :
68832
Announced Date :
30/07/2012
Type :
Acquisition of Minority Stake
Deal Value :
Yes
Acquirer :
Fund raising led by Azulis Capital and Galia Gestion
Target :
SELAS Bio-Clinic
Country :
France
Sector of activity :
- Laboratories > Pharmaceuticals & Cosmetics > Health, Pharmaceuticals & Biotechnology > Medical Diagnostic Laboratory
Business Description :
Founded in 1995, Bioclinic is an independent medical analysis lab networks in the Paris region. > It comprises 20 laboratories in 5 of the region's 7 departements.
Transaction multiples available
| EV/ Sales |
EV/ Gross Profit |
EV/ EBITDA |
EV/ EBIT |
Eq/ PBT |
P/E | Price to Book |
Specific multiple(s) |
|
|---|---|---|---|---|---|---|---|---|
| Historic | 
|
|||||||
| Current |
|
Rating :
*
|
|
Multiple available |
| n.s. | Multiple calculated, but not significant |
Source: Epsilon Research / EMAT
Comparable Transactions
- Number of EMAT Reports / sub-sector « Medical Diagnostic Laboratory » = 55
| Date | Acquirer | Target | Country | Multiples | See details |
| 30/07/2014 | Labco | SDN (SDN Istituto di Ricerca Diagnostica e Nucleare) | Italy | ** | 68804 |
| 14/11/2014 | Recipharm | Lusomedicamenta-sociedade Tecnica Farmaceutica | Portugal | *** | 68626 |
Source: Epsilon Research / EMAT
